Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation
Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential.
Nektar Therapeutics (NKTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 1,679 | $95,535 | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.28 | 15,000 | $259,200.00 | 107,668 | 2019-09-05 | Filing | |
| $59.80 | 1,400 | $83,720.00 | 177,000 | 2018-06-06 | Filing | |
| $59.07 | 2,000 | $118,140.00 | 175,600 | 2018-06-06 | Filing | |
| $55.22 | 1,600 | $88,352.00 | 173,600 | 2018-06-05 | Filing | |
| $17.95 | 35,000 | $628,250.00 | 133,000 | 2017-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $48.18 | 1,210 | $58,297.80 | 49,342 | 2025-09-09 | Filing | |
| $47.49 | 2,156 | $102,388.44 | 50,552 | 2025-09-09 | Filing | |
| $46.41 | 1,200 | $55,692.00 | 52,708 | 2025-09-09 | Filing | |
| $45.16 | 2,100 | $94,836.00 | 53,908 | 2025-09-09 | Filing | |
| $35.69 | 307 | $10,956.83 | 17,462 | 2025-09-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 323,246 | $18,392,697 | 0.59% | |
| 2. | 233,205 | $13,269,365 | 0.69% | |
| 3. | 87,174 | $4,960,201 | 0.09% | |
| 4. | 73,716 | $4,194,440 | 0.8% | |
| 5. | 9,244 | $525,984 | 0% |
News See All
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Call Transcript
Operator: Welcome to the Nektar Therapeutics Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin
Nektar Therapeutics (NASDAQ:NKTR) is one of the Stocks With Huge Catalysts on the Horizon. On June 24, Nektar Therapeutics (NASDAQ:NKTR) announced positive results from the Phase 2b REZOLVE-AD trial...
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin
Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts.
11 Best Hot Stocks to Buy According to Wall Street Analysts
On July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into the second half of the ...
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil
The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%.
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
